Beneficial effects of omega-3 fatty acids on low density lipoprotein particle size in patients with type 2 diabetes already under statin therapy

Myung Won Lee, Jeong Kyung Park, Jae Won Hong, Kwang Joon Kim, Dong Yeob Shin, Chul Woo Ahn, Young Duk Song, Hong Keun Cho, Seok Won Park, Eun Jig Lee

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Beyond statin therapy for reducing low density lipoprotein cholesterol (LDL-C), additional therapeutic strategies are required to achieve more optimal reduction in cardiovascular risk among diabetic patients with dyslipidemia. To evaluate the effects and the safety of combined treatment with omega-3 fatty acids and statin in dyslipidemic patients with type 2 diabetes, we conducted a randomized, open-label study in Korea. Patients with persistent hypertriglyceridemia (≥200 mg/dL) while taking statin for at least 6 weeks were eligible. Fifty-one patients were randomized to receive either omega-3 fatty acid 4, 2 g, or no drug for 8 weeks while continuing statin therapy. After 8 weeks of treatment, the mean percentage change of low density lipoprotein (LDL) particle size and triglyceride (TG) level was greater in patients who were prescribed 4 g of omega-3 fatty acid with statin than in patients receiving statin monotherapy (2.8%±3.1% vs. 2.3%±3.6%, P=0.024; -41.0%±24.1% vs. -24.2%±31.9%, P= 0.049). Coadministration of omega-3 fatty acids with statin increased LDL particle size and decreased TG level in dyslipidemic patients with type 2 diabetes. The therapy was well tolerated without significant adverse effects.

Original languageEnglish
Pages (from-to)207-211
Number of pages5
JournalDiabetes and Metabolism Journal
Volume37
Issue number3
DOIs
Publication statusPublished - 2013 Jun 1

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Omega-3 Fatty Acids
LDL Lipoproteins
Particle Size
Type 2 Diabetes Mellitus
Therapeutics
Triglycerides
Hypertriglyceridemia
Korea
Dyslipidemias
LDL Cholesterol
Safety
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism

Cite this

Lee, Myung Won ; Park, Jeong Kyung ; Hong, Jae Won ; Kim, Kwang Joon ; Shin, Dong Yeob ; Ahn, Chul Woo ; Song, Young Duk ; Cho, Hong Keun ; Park, Seok Won ; Lee, Eun Jig. / Beneficial effects of omega-3 fatty acids on low density lipoprotein particle size in patients with type 2 diabetes already under statin therapy. In: Diabetes and Metabolism Journal. 2013 ; Vol. 37, No. 3. pp. 207-211.
@article{2b61e0de34524962af2a2480acdc630b,
title = "Beneficial effects of omega-3 fatty acids on low density lipoprotein particle size in patients with type 2 diabetes already under statin therapy",
abstract = "Beyond statin therapy for reducing low density lipoprotein cholesterol (LDL-C), additional therapeutic strategies are required to achieve more optimal reduction in cardiovascular risk among diabetic patients with dyslipidemia. To evaluate the effects and the safety of combined treatment with omega-3 fatty acids and statin in dyslipidemic patients with type 2 diabetes, we conducted a randomized, open-label study in Korea. Patients with persistent hypertriglyceridemia (≥200 mg/dL) while taking statin for at least 6 weeks were eligible. Fifty-one patients were randomized to receive either omega-3 fatty acid 4, 2 g, or no drug for 8 weeks while continuing statin therapy. After 8 weeks of treatment, the mean percentage change of low density lipoprotein (LDL) particle size and triglyceride (TG) level was greater in patients who were prescribed 4 g of omega-3 fatty acid with statin than in patients receiving statin monotherapy (2.8{\%}±3.1{\%} vs. 2.3{\%}±3.6{\%}, P=0.024; -41.0{\%}±24.1{\%} vs. -24.2{\%}±31.9{\%}, P= 0.049). Coadministration of omega-3 fatty acids with statin increased LDL particle size and decreased TG level in dyslipidemic patients with type 2 diabetes. The therapy was well tolerated without significant adverse effects.",
author = "Lee, {Myung Won} and Park, {Jeong Kyung} and Hong, {Jae Won} and Kim, {Kwang Joon} and Shin, {Dong Yeob} and Ahn, {Chul Woo} and Song, {Young Duk} and Cho, {Hong Keun} and Park, {Seok Won} and Lee, {Eun Jig}",
year = "2013",
month = "6",
day = "1",
doi = "10.4093/dmj.2013.37.3.207",
language = "English",
volume = "37",
pages = "207--211",
journal = "Diabetes and Metabolism Journal",
issn = "2233-6079",
publisher = "Korean Diabetes Association",
number = "3",

}

Beneficial effects of omega-3 fatty acids on low density lipoprotein particle size in patients with type 2 diabetes already under statin therapy. / Lee, Myung Won; Park, Jeong Kyung; Hong, Jae Won; Kim, Kwang Joon; Shin, Dong Yeob; Ahn, Chul Woo; Song, Young Duk; Cho, Hong Keun; Park, Seok Won; Lee, Eun Jig.

In: Diabetes and Metabolism Journal, Vol. 37, No. 3, 01.06.2013, p. 207-211.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Beneficial effects of omega-3 fatty acids on low density lipoprotein particle size in patients with type 2 diabetes already under statin therapy

AU - Lee, Myung Won

AU - Park, Jeong Kyung

AU - Hong, Jae Won

AU - Kim, Kwang Joon

AU - Shin, Dong Yeob

AU - Ahn, Chul Woo

AU - Song, Young Duk

AU - Cho, Hong Keun

AU - Park, Seok Won

AU - Lee, Eun Jig

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Beyond statin therapy for reducing low density lipoprotein cholesterol (LDL-C), additional therapeutic strategies are required to achieve more optimal reduction in cardiovascular risk among diabetic patients with dyslipidemia. To evaluate the effects and the safety of combined treatment with omega-3 fatty acids and statin in dyslipidemic patients with type 2 diabetes, we conducted a randomized, open-label study in Korea. Patients with persistent hypertriglyceridemia (≥200 mg/dL) while taking statin for at least 6 weeks were eligible. Fifty-one patients were randomized to receive either omega-3 fatty acid 4, 2 g, or no drug for 8 weeks while continuing statin therapy. After 8 weeks of treatment, the mean percentage change of low density lipoprotein (LDL) particle size and triglyceride (TG) level was greater in patients who were prescribed 4 g of omega-3 fatty acid with statin than in patients receiving statin monotherapy (2.8%±3.1% vs. 2.3%±3.6%, P=0.024; -41.0%±24.1% vs. -24.2%±31.9%, P= 0.049). Coadministration of omega-3 fatty acids with statin increased LDL particle size and decreased TG level in dyslipidemic patients with type 2 diabetes. The therapy was well tolerated without significant adverse effects.

AB - Beyond statin therapy for reducing low density lipoprotein cholesterol (LDL-C), additional therapeutic strategies are required to achieve more optimal reduction in cardiovascular risk among diabetic patients with dyslipidemia. To evaluate the effects and the safety of combined treatment with omega-3 fatty acids and statin in dyslipidemic patients with type 2 diabetes, we conducted a randomized, open-label study in Korea. Patients with persistent hypertriglyceridemia (≥200 mg/dL) while taking statin for at least 6 weeks were eligible. Fifty-one patients were randomized to receive either omega-3 fatty acid 4, 2 g, or no drug for 8 weeks while continuing statin therapy. After 8 weeks of treatment, the mean percentage change of low density lipoprotein (LDL) particle size and triglyceride (TG) level was greater in patients who were prescribed 4 g of omega-3 fatty acid with statin than in patients receiving statin monotherapy (2.8%±3.1% vs. 2.3%±3.6%, P=0.024; -41.0%±24.1% vs. -24.2%±31.9%, P= 0.049). Coadministration of omega-3 fatty acids with statin increased LDL particle size and decreased TG level in dyslipidemic patients with type 2 diabetes. The therapy was well tolerated without significant adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=84879467569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879467569&partnerID=8YFLogxK

U2 - 10.4093/dmj.2013.37.3.207

DO - 10.4093/dmj.2013.37.3.207

M3 - Article

C2 - 23807924

AN - SCOPUS:84879467569

VL - 37

SP - 207

EP - 211

JO - Diabetes and Metabolism Journal

JF - Diabetes and Metabolism Journal

SN - 2233-6079

IS - 3

ER -